0
Summaries for Patients |

Can a New Antibiotic Safely Prevent Travelers' Diarrhea? FREE

[+] Article and Author Information

The summary below is from the full report titled “A Randomized, Double-Blind, Placebo-Controlled Trial of Rifaximin To Prevent Travelers' Diarrhea.” It is in the 17 May 2005 issue of Annals of Internal Medicine (volume 142, pages 805-812). The authors are H.L. DuPont, Z.-D. Jiang, P.C. Okhuysen, C.D. Ericsson, F. Javier de la Cabada, S. Ke, M.W. DuPont, and F. Martinez-Sandoval.


Ann Intern Med. 2005;142(10):I-30. doi:10.7326/0003-4819-142-10-200505170-00001
Text Size: A A A

What is the problem and what is known about it so far?

Travelers to developing countries often develop diarrhea, which is usually caused by consuming food or water contaminated with bacteria. Daily antibiotics can prevent travelers' diarrhea but have many adverse effects, such as making bacteria in the body more resistant to antibiotics. Therefore, the risk of taking daily antibiotics to prevent travelers' diarrhea is usually considered greater than the benefit. Rifaximin, an antibiotic used in other countries to treat diarrhea, recently became available in the United States. Rifaximin is an effective treatment for travelers' diarrhea once it has developed and might also be useful for preventing travelers' diarrhea.

Why did the researchers do this particular study?

To see if rifaximin is safe and effective when taken to prevent travelers' diarrhea.

Who was studied?

210 students from the United States who were attending classes in Guadalajara, Mexico. The students were at risk for travelers' diarrhea because they lived with local families. All were older than age 18 years and were generally healthy.

How was the study done?

The researchers randomly assigned the students to take rifaximin or placebo for 2 weeks after their arrival in Mexico. They asked the students to keep a diary of symptoms and then compared how many people developed diarrhea or adverse drug effects. They also checked to see if the antibiotic led to changes in the kinds of normal bacteria that live in the gut and in the antibiotic resistance of those bacteria.

What did the researchers find?

Approximately 15% of students who took rifaximin and more than 50% of the students who took placebo developed diarrhea. Side effects were similar in all groups. No important changes in the type of gut bacteria or the antibiotic resistance of those bacteria were detected in students taking the antibiotic.

What are the limitations of the study?

The study findings may not apply to areas where travelers' diarrhea is caused by bacteria different from those in Mexico. They also do not apply to travelers' diarrhea caused by viruses, against which antibiotics have no effect. The study duration was 4 to 5 weeks. Findings might differ over longer time periods.

What are the implications of the study?

Rifaximin appears to prevent travelers' diarrhea in Mexico when taken daily for 2 weeks. It is not a substitute for careful selection and preparation of food and water to avoid infection.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)